ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Mechanistic Insights into the Anti-Virulence Effects ofAntibiotics (Basel, Switzerland) · 2026Article
- Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Hyaluronic Acid-Based Nanomotors: Crossing Mucosal Barriers to Tackle Antimicrobial Resistance.ACS applied materials & interfaces · 2025Article
- Modifying Pharmacokinetic Properties of the Gram-Negative Bacteria Targeting Endolysin ML06 Without Affecting Antibacterial Activity.International journal of molecular sciences · 2025Article
- Sodium houttuyfonate inhibits the cariogenic virulence ofJournal of oral microbiology · 2025Article
- Biofilm targeting with chitosan-based nanohydrogel containing Quercus infectoria G. Olivier extract against Streptococcus mutans: new formulations of a traditional natural product.BMC complementary medicine and therapies · 2024Article
- Effect of Nk-lysin peptides on bacterial growth, MIC, antimicrobial resistance, and viral activities.Animal biotechnology · 2024Article
- Application of microbial enzymes in medicine and industry: current status and future perspectives.Future microbiology · 2024Review
- Small-Molecule Antibiotic Drug Development: Need and Challenges.ACS infectious diseases · 2023Review
- Probing the Gelation Synergies and Anti-ACS omega · 2023Article
- Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations.Frontiers in medicine · 2022Article
- Antimicrobial Use and Management of Childhood Diarrhea at Community Drug Retail Outlets in Eastern Ethiopia: A Matched Questionnaire-Based and Simulated Patient-Case Study.Pediatric health, medicine and therapeutics · 2022Article
- Recent advances and challenges in antibacterial drug development.ADMET & DMPK · 2022Article
- What Is New in the Anti-Frontiers in cellular and infection microbiology · 2022Review
- Natural products from traditional medicine as promising agents targeting at different stages of oral biofilm development.Frontiers in microbiology · 2022Review
- Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?Critical care explorations · 2021Review
- Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections.Antibiotics (Basel, Switzerland) · 2021Review
- Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine.Expert review of anti-infective therapy · 2020Review
- Targeting Parasite-Produced Macrophage Migration Inhibitory Factor as an Antivirulence Strategy With Antibiotic-Antibody Combination to Reduce Tissue Damage.The Journal of infectious diseases · 2020Article
- Appropriate Use and Future Directions of Molecular Diagnostic Testing.Current infectious disease reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Due to increasing rates of antimicrobial-resistant infections and the current inadequacy of the antibiotic pipeline, there is increasing interest in nontraditional approaches to antibacterial therapies. We define "traditional" agents as small-molecule agents that directly target bacterial components to exert a bacteriostatic or bactericidal effect, and "nontraditional approaches" as antimicrobial therapeutics that work through other means (ie, not a small molecule and/or utilizes a nontraditional target). Due to their atypical features, such therapies may be less susceptible to the emergence of resistance than traditional antibiotics. They include approaches such as monoclonal antibodies, virulence disruptors, immunomodulators, phage therapies, microbiome-based therapies, antibiotic potentiators, and antisense approaches. This article discusses both the developmental and regulatory advantages and challenges associated with each of these technologies. By identifying existing regulatory and developmental gaps, we hope to provide a sense of where focusing resources may provide the greatest impact on successful product development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.